Zentalis Pharmaceuticals, Inc. Earnings Per Share (Basic)
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Earnings Per Share (Basic) of -$0.59 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- Zentalis Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.59.
- Zentalis Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.50.
- Zentalis Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.49.
- Zentalis Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.37.
- Zentalis Pharmaceuticals, Inc. earnings per share, basic for fiscal 2025 was -$1.91.
- Zentalis Pharmaceuticals, Inc. earnings per share, basic for fiscal 2024 was -$2.33.
- Zentalis Pharmaceuticals, Inc. earnings per share, basic for fiscal 2023 was -$4.47.
- Zentalis Pharmaceuticals, Inc. earnings per share, basic for fiscal 2022 was -$4.48.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.59 10-Q · filed 2026-08-06 | -$1.10 10-Q · filed 2026-08-06 | -$1.59 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.96 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | -$0.50 10-Q · filed 2026-05-12 | -$0.99 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$1.36 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$1.74 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | -$0.49 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.86 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.23 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.91 10-K · filed 2026-03-26 |
| 2025-09-30 | -$0.37 10-Q · filed 2025-11-10 | -$0.74 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.42 10-Q · filed 2025-11-10 | -$2.08 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | -$0.37 10-Q · filed 2026-08-06 | -$1.05 10-Q · filed 2026-08-06 | -$1.71 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.28 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | -$0.67 10-Q · filed 2026-05-12 | -$1.34 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$1.91 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$3.15 derived: net income ÷ weighted average shares · filed 2026-05-12 |
| 2024-12-31 | -$0.67 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.23 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$2.47 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$2.33 10-K · filed 2026-03-26 |
| 2024-09-30 | -$0.56 10-Q · filed 2025-11-10 | -$1.81 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$1.67 10-Q · filed 2025-11-10 | -$2.53 derived: net income ÷ weighted average shares · filed 2026-04-30 |
| 2024-06-30 | -$1.24 10-Q · filed 2025-08-06 | -$1.10 10-Q · filed 2025-08-06 | -$1.96 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$2.75 derived: net income ÷ weighted average shares · filed 2026-04-30 |
| 2024-03-31 | $0.14 10-Q · filed 2025-05-14 | -$0.72 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.50 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$3.21 derived: net income ÷ weighted average shares · filed 2026-04-30 |
| 2023-12-31 | -$0.86 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.65 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$3.40 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$4.47 10-K · filed 2026-03-26 |
| 2023-09-30 | -$0.79 10-Q · filed 2024-11-12 | -$2.56 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$3.64 10-Q · filed 2024-11-12 | -$4.60 derived: net income ÷ weighted average shares · filed 2025-03-26 |
| 2023-06-30 | -$1.85 10-Q · filed 2024-08-09 | -$2.93 10-Q · filed 2024-08-09 | -$3.88 derived: net income ÷ weighted average shares · filed 2025-03-26 | -$4.85 derived: net income ÷ weighted average shares · filed 2025-03-26 |
| 2023-03-31 | -$1.07 10-Q · filed 2024-05-07 | -$2.01 derived: net income ÷ weighted average shares · filed 2025-03-26 | -$2.97 derived: net income ÷ weighted average shares · filed 2025-03-26 | -$4.28 derived: net income ÷ weighted average shares · filed 2025-03-26 |
| 2022-12-31 | -$0.95 derived: net income ÷ weighted average shares · filed 2025-03-26 | -$1.90 derived: net income ÷ weighted average shares · filed 2025-03-26 | -$3.21 derived: net income ÷ weighted average shares · filed 2025-03-26 | -$4.48 10-K · filed 2025-03-26 |
| 2022-09-30 | -$0.96 10-Q · filed 2023-11-06 | -$2.27 derived: net income ÷ weighted average shares · filed 2023-11-06 | -$3.56 10-Q · filed 2023-11-06 | -$4.68 derived: net income ÷ weighted average shares · filed 2023-11-06 |
| 2022-06-30 | -$1.34 10-Q · filed 2023-08-09 | -$2.64 10-Q · filed 2023-08-09 | -$3.77 derived: net income ÷ weighted average shares · filed 2023-08-09 | -$3.91 derived: net income ÷ weighted average shares · filed 2023-08-09 |
| 2022-03-31 | -$1.31 10-Q · filed 2023-05-10 | -$2.42 derived: net income ÷ weighted average shares · filed 2023-05-10 | -$2.52 derived: net income ÷ weighted average shares · filed 2023-05-10 | -$3.83 derived: net income ÷ weighted average shares · filed 2023-05-10 |
| 2021-12-31 | -$1.11 10-K · filed 2022-02-24 | -$1.21 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$2.51 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$3.72 10-K · filed 2024-02-27 |
| 2021-09-30 | -$0.09 10-Q · filed 2022-11-09 | -$1.38 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$2.59 10-Q · filed 2022-11-09 | -$3.60 derived: net income ÷ weighted average shares · filed 2022-11-09 |
| 2021-06-30 | -$1.34 10-Q · filed 2022-08-09 | -$2.58 10-Q · filed 2022-08-09 | -$3.59 derived: net income ÷ weighted average shares · filed 2022-08-09 | -$4.51 derived: net income ÷ weighted average shares · filed 2022-08-09 |
| 2021-03-31 | -$1.24 10-Q · filed 2022-05-05 | -$2.25 derived: net income ÷ weighted average shares · filed 2022-05-05 | -$3.17 derived: net income ÷ weighted average shares · filed 2022-05-05 | -$3.97 derived: net income ÷ weighted average shares · filed 2022-05-05 |
| 2020-12-31 | -$1.01 10-K · filed 2022-02-24 | -$1.92 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$2.72 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$4.19 10-K · filed 2023-03-01 |
| 2020-09-30 | -$0.91 10-K · filed 2022-02-24 | -$1.70 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$3.21 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$0.78 10-K · filed 2022-02-24 | -$2.53 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$2.88 10-K · filed 2022-02-24 | |||
| 2019-12-31 | -$8.16 derived: net income ÷ weighted average shares · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |